Pacira touts Phase IV study of Exparel anesthetic in total knee arthroplasty

Pacira Pharmaceuticals (NSDQ:PCRX) said today the Phase IV study of its Exparel bupivacaine liposome injection in patients undergoing total knee arthroplasty met its co-primary endpoints for postsurgical pain and opioid reduction.

The anesthetic achieved statistical significance for secondary endpoints including time to 1st opioid use and the percentage of patients who did not require opioids following the procedure.

Get the full story at our sister site, Drug Delivery Business News.

The post Pacira touts Phase IV study of Exparel anesthetic in total knee arthroplasty appeared first on MassDevice.

from MassDevice http://ift.tt/2nBZt7z